Australia childhood vaccine schedule: 11 vaccines by age
For babies (first year): Hepatitis B, DTaP / Tdap, Polio (IPV), Hib, Pneumococcal (PCV), Rotavirus, MMR, Varicella (chickenpox), Meningococcal. Click a vaccine for its Australia-specific page and its schedule in every other country.
| Vaccine | Status | Doses & recommended age |
|---|---|---|
| Hepatitis B · side effects & data | Universal | Dose 1 — At birth (Monovalent then hexavalent) Dose 2 — 2 months (Monovalent then hexavalent) Dose 3 — 4 months (Monovalent then hexavalent) Dose 4 — 6 months (Monovalent then hexavalent) |
| DTaP / Tdap · side effects & data | Universal | Dose 1 — 2 months Dose 2 — 4 months Dose 3 — 6 months Booster — 18 months Booster — 4 years |
| Polio (IPV) · side effects & data | Universal | Dose 1 — 2 months (IPV) Dose 2 — 4 months (IPV) Dose 3 — 6 months (IPV) Booster — 4 years (IPV) |
| Hib · side effects & data | Universal | Dose 1 — 2 months Dose 2 — 4 months Dose 3 — 6 months Booster — 18 months |
| Pneumococcal (PCV) · side effects & data | Universal | Dose 1 — 2 months Dose 2 — 4 months Dose 3 — 6 months Booster — 12 months |
| Rotavirus · side effects & data | Universal | Dose 1 — 2 months (Rotavirus (oral)) Dose 2 — 4 months (Rotavirus (oral)) Dose 3 — 6 months (Rotavirus (oral)) |
| MMR · side effects & data | Universal | Dose 1 — 12 months (MMR or MMRV) Dose 2 — 18 months (MMR or MMRV) |
| Varicella (chickenpox) · side effects & data | Universal | Dose 1 — 18 months (MMRV) |
| Meningococcal · side effects & data | Selective / risk-based | MenB dose 1 — 2 months (MenB then MenACWY) MenB dose 2 — 4 months (MenB then MenACWY) MenB booster — 12 months (MenB then MenACWY) MenACWY — 12 months (MenB then MenACWY) MenACWY — 14-16 years (MenB then MenACWY) |
| HPV · side effects & data | Universal | Dose 1 — 12-13 years Dose 2 — 6-12 months after dose 1 |
| Influenza (flu) · side effects & data | Universal | Annual — 6 months-5 years and risk groups, every season |
Australia vaccine schedule vs. the United States
Australia and the United States share 11 routine vaccines. The U.S. routinely gives Hepatitis A, COVID-19, which Australia does not.
| Vaccine | Australia first dose | U.S. first dose | Doses |
|---|---|---|---|
| Hepatitis B | At birth | Birth | 4 vs 3 doses |
| DTaP / Tdap | 2 months | 2 months | 5 vs 5 doses |
| Polio (IPV) | 2 months | 2 months | 4 vs 4 doses |
| Hib | 2 months | 2 months | 4 vs 4 doses |
| Pneumococcal (PCV) | 2 months | 2 months | 4 vs 4 doses |
| Rotavirus | 2 months | 2 months | 3 vs 3 doses |
| MMR | 12 months | 12-15 months | 2 vs 2 doses |
| Varicella (chickenpox) | 18 months | 12-15 months | 1 vs 2 doses |
| Meningococcal | 2 months | 11-12 years | 5 vs 2 doses |
| HPV | 12-13 years | 11-12 years | 2 vs 2 doses |
| Influenza (flu) | 6 months-5 years and risk groups, every season | 6 months and older, every season | 1 vs 1 doses |
In the routine U.S. schedule but not Australia's: Hepatitis A, COVID-19.
Why Australia's schedule looks the way it does
Schedules differ mostly because disease burden and health-system conditions differ. WHO/UNICEF estimates of how many children actually receive each vaccine, and the diseases' reported incidence, explain most of the choices below.
- Tuberculosis: 6.9 new cases per 100,000 people per year (2024). BCG is not in the national schedule. BCG mainly protects young children from severe TB (meningitis, miliary TB), so countries with high TB incidence give it at birth and low-incidence countries reserve it for risk groups.
- Measles: 6.7 reported cases per million people (2025). Two-dose coverage is 91%; sustained elimination needs roughly 95% coverage with both doses, which is why schedules add or move the second dose when coverage or outbreaks change.
- Hepatitis B birth dose: 65% coverage. A birth dose matters most where mothers commonly carry hepatitis B, because infection at birth becomes chronic in most infants; countries with low carriage and universal prenatal screening often start hepatitis B vaccination later or target only exposed newborns.
Coverage: share of children who received each vaccine (WHO/UNICEF estimates)
| Vaccine | Australia | United States |
|---|---|---|
| BCG (TB) | not reported | not reported |
| DTP dose 1 | 92% (2025) | 98% (2025) |
| DTP dose 3 | 92% (2025) | 94% (2025) |
| Measles dose 1 | 91% (2025) | 92% (2025) |
| Measles dose 2 | 91% (2025) | 95% (2025) |
| Polio (IPV series) | 93% (2025) | 93% (2025) |
| Hep B birth dose | 65% (2025) | 75% (2025) |
| Hep B dose 3 | 94% (2025) | 93% (2025) |
| Hib dose 3 | 92% (2025) | 92% (2025) |
| Pneumococcal (PCV) | 94% (2025) | 84% (2025) |
| Rotavirus (complete) | 68% (2025) | 77% (2025) |
| HPV dose 1, girls | 75% (2025) | 73% (2025) |
Source: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and WHO reported incidence, via the WHO Immunization Data portal; TB incidence from the WHO Global Health Observatory (indicator MDG_0000000020). Retrieved 2026-10-09. "Not reported" usually means the vaccine is not in the universal schedule. Polio is the completed inactivated-polio series (IPVC).
Other Asia-Pacific countries
Indonesia · Japan · Philippines · South Korea · Vietnam · all 31 countries